Jpn. J. Infect. Dis., 65 (3), 240-242, 2012
To see a printable version of the article in the Adobe file format, click this [PDF] link.
Caie Yang1, Hong Lei1, Di Wang2, Xianghong Meng1, Jufang He1, Aihua Tong1, Lei Zhu1, Ying Jiang1, and Mei Dong1*
1Department of Clinical Laboratory, 309th Hospital of Chinese People's Liberation Army, and 2309th Hospital of Chinese People's Liberation Army, Beijing, China
(Received November 10, 2011. Accepted February 6, 2012)
*Corresponding author: Mailing address: Department of Clinical Laboratory, PLA 309 Hospital, Beijing 100091, China. Tel & Fax: +86-10-66775937, E-mail: このメールアドレスはスパムボットから保護されています。閲覧するにはJavaScriptを有効にする必要があります。
SUMMARY: The in vitro activity of linezolid was evaluated against 84 clinical isolates of Mycobacterium tuberculosis, including multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains, isolated from the center for tuberculosis research and treatment of the Chinese army. Linezolid showed excellent activity, with minimum inhibitory concentrations (MICs) of 0.125–0.5 μg/mL against all tested isolates. There were no differences in the MIC50 and MIC90 of linezolid between susceptible, isoniazid-resistant, MDR, and XDR. Indeed, all of the groups displayed identical MIC90 values of 0.25 μg/mL, which is lower than previously reported in similar studies. We conclude that linezolid may be a more effective drug against M. tuberculosis and may play an important role in treating drug-resistant tuberculosis in China.
